Compass Therapeutics Company Insiders
| CMPX Stock | USD 5.19 -0.40 -7.16% |
About 66 percent of all Compass Therapeutics' insiders are acquiring. The analysis of the overall insider sentiment regarding Compass Therapeutics suggests that a large number of insiders are confidant. Compass Therapeutics employs about 39 people. The company is managed by 15 executives with a total tenure of roughly 91 years, averaging almost 6.0 years of service per executive, having 2.6 employees per reported executive.
Insider Sentiment
Mostly Buying
Selling | Buying |
Latest Trades
| 2025-05-27 | Thomas J Schuetz | Acquired 10000 @ 2.11 | View | ||
| 2025-04-09 | Carl L Gordon | Disposed 3571428 @ 1.59 | View | ||
| 2025-04-07 | Jonathan Anderman | Acquired 20000 @ 1.54 | View |
Following insider trading sentiment in Compass Therapeutics can help investors add context around confidence, timing, and operating risk while the public narrative is still evolving. The signal is still regulated and disclosed under securities law, which is why the public filing record matters more than rumor or interpretation alone.
Compass Therapeutics has a market cap of 994.25 M, ROE of -41.29%. See Trending Equities for portfolio-level analysis. This suggests a position in Compass Therapeutics across the allocation. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.Compass Therapeutics' Workforce Through the Years
A workforce review of Compass Therapeutics matters because hiring and staffing trends often say something about growth plans, cost discipline, and management expectations. Current projections suggest a workforce around about 40 employees by April 2026, which should be reviewed alongside revenue and margin trends.Macro event markers
Compass Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of -25.29 % implying that it lost $25.29 for every $100 of assets on its balance sheet. This is materially lower than the sector median. Similarly, it shows a return on stockholder's equity (ROE) of -41.29 %, indicating that stockholder equity declined rather than grew.As of last month (February 2026), Common Stock Shares Outstanding is forecasted to soften to approximately 96.7 M. In addition to that, Net Loss is forecasted to soften to approximately -37.1 M
Stock Ownership Analysis
About 88.0% of the company shares are held by institutions such as insurance companies. The book value of Compass Therapeutics was currently reported as 1.1. The company recorded a loss per share of 0.45. Compass Therapeutics had not issued any dividends in recent years.Reviewing share-based compensation in Compass Therapeutics helps investors understand how management balances employee incentives against dilution risk. Shares outstanding are near 177.9 M. That is why investors should compare compensation intensity with revenue growth, margin progress, and free-cash-flow generation.
Compass Therapeutics Quarterly Liabilities And Stockholders Equity | 219.59 Million |
Insider Trades History
Reviewing insider ownership in Compass Therapeutics helps investors understand how much of the equity base is controlled by people involved in running the business. Insiders currently hold about 11.14% of outstanding shares. Investors usually want to know whether that level supports alignment without creating excessive control risk. View all of Compass Therapeutics' insider trades
Macro event markers
Stock Institutional Investors
Institutional ownership matters in Compass Therapeutics because pension funds, mutual funds, banks, and advisers can materially influence liquidity, governance, and price discovery. Used correctly, institutional data helps investors understand who may be setting the marginal price and how resilient that holder base could be under stress.
| Shares | Jpmorgan Chase & Co | 2025-09-30 | 4 M | Rock Springs Capital Management Lp | 2025-12-31 | 3.9 M | Deerfield Management Co | 2025-12-31 | 3.6 M | Blue Owl Capital Holdings Lp | 2025-12-31 | 3.5 M | Sofinnova Ventures | 2025-12-31 | 3.4 M | Millennium Management Llc | 2025-09-30 | 3.2 M | State Street Corp | 2025-09-30 | 3.1 M | Geode Capital Management, Llc | 2025-09-30 | 2.9 M | Braidwell Lp | 2.8 M | Tang Capital Management Llc | 2025-09-30 | 16.8 M | Orbimed Advisors, Llc | 2025-09-30 | 15.2 M |
Insider Trading Activities
Insider trading disclosures for Compass Therapeutics offer a structured way to watch how people closest to the business are behaving while expectations change across the market. Current market capitalization is about 994.25 Million. Used properly, these records are better for context than for blind buy-or-sell signals.
Outstanding Bonds
Reviewing Compass Therapeutics bond obligations helps investors understand how much of the business is financed with fixed-income capital rather than purely with equity. This is why bond analysis is not just a credit exercise; it also informs equity holders about solvency, optionality, and future capital-allocation pressure.
| US20451RAC60 Corp BondUS20451RAC60 | View | |
| US20451RAB87 Corp BondUS20451RAB87 | View | |
| Compass Minerals International Corp BondUS20451NAG60 | View |
Corporate Filings
| 12th of March 2026 Other Reports | ViewVerify | |
8K | 5th of March 2026 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 13th of February 2026 An amended filing to the original Schedule 13G | ViewVerify |
F4 | 10th of February 2026 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 21st of January 2026 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
F4 | 12th of January 2026 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 7th of January 2026 Other Reports | ViewVerify | |
8K | 6th of January 2026 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Shares in Circulation | First Issued 2018-06-30 | Previous Quarter 138.3 M | Current Value 184.8 M | Average Shares Outstanding 89.6 M | Quarterly Volatility 47.7 M |
Macro event markers
Compass Stock Holders Distribution
Institutional ownership analysis for Compass Therapeutics matters because banks, hedge funds, pension plans, and other professional investors can influence price and liquidity more forcefully than smaller holders. This matters because getting in early on a sponsorship cycle may help, but getting caught near a large-holder exit can have the opposite effect.
Compass Therapeutics Market Cap and Value
Compass Therapeutics Workforce Comparison
Compass Therapeutics is rated below average in number of employees among leading competitors. The total workforce of Health Care industry is currently estimated at about 1,506. Compass Therapeutics holds roughly 39.0 in number of employees claiming about 2.59% of equities under Health Care sector.
Compass Therapeutics Insider Trading History
Insider trading disclosures for Compass Therapeutics offer a structured way to watch how people closest to the business are behaving while expectations change across the market. Current market capitalization is about 994.25 Million. Used properly, these records are better for context than for blind buy-or-sell signals.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2026-03-01 | 8.0 | 16 | 2 | 6,952,500 | 83,464 |
| 2025-06-01 | 1.5 | 3 | 2 | 50,000 | 7,142,856 |
| 2025-03-01 | 5.0 | 10 | 2 | 2,470,000 | 99,741 |
| 2024-09-01 | 0.1667 | 1 | 6 | 300,000 | 425,000 |
| 2024-03-01 | 5.0 | 10 | 2 | 5,021,250 | 93,980 |
| 2022-12-01 | 0.6667 | 2 | 3 | 804,000 | 24,500 |
| 2022-06-01 | 13.5 | 27 | 2 | 1,111,303 | 0.00 |
| 2021-06-01 | 3.0 | 3 | 1 | 2,101,549 | 0.00 |
| 2020-06-01 | 1.2 | 6 | 5 | 3,610,879 | 0.00 |
| 2006-03-01 | 0.2 | 2 | 10 | 60,000 | 663,572 |
| 2005-12-01 | 1.0 | 1 | 1 | 19,000 | 19,000 |
Compass Therapeutics Notable Stakeholders
Stakeholders matter for Compass Therapeutics because not every influential participant is a shareholder acting with the same objective or time horizon. This becomes more informative when investors want to understand not just ownership, but influence, incentives, and strategic pressure points.
| Jonathan JD | General President | Profile | |
| James Kranz | VP Controls | Profile | |
| Susan Kalled | Chief Officer | Profile | |
| Cynthia MD | Chief Officer | Profile | |
| Anna Gifford | Communications Manager | Profile | |
| Karin BA | Senior Operations | Profile | |
| Vered MBA | Pres COO | Profile | |
| MBA JD | Chief Officer | Profile | |
| MD MBA | Chief Officer | Profile | |
| Barry JD | Chief Officer | Profile | |
| Neil CPA | Senior Officer | Profile | |
| Peter Moesta | Interim CMC | Profile | |
| Bing Gong | Chief Officer | Profile | |
| MPH MBA | Chief Officer | Profile | |
| Minori MD | Senior Development | Profile |
Management Information & Data Sources
Compass Therapeutics is a small-cap company in Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care. Executive review focuses on insiders, senior management, and employee signals. Leadership review helps frame whether management actions match reported operating results. Compass Therapeutics employs 39 people.
Reported values for Compass Therapeutics are derived from periodic company reporting and market reference feeds and then standardized by Macroaxis analytics. Refresh times depend on source availability. Insider and management fields are mapped from published filings and company disclosures.
This content is curated and reviewed by:
Ellen Johnson - Member of Macroaxis Editorial BoardWorkforce Efficiency and Productivity
Investors reviewing Compass Therapeutics can use workforce efficiency as another lens on execution, especially when comparing similar businesses in the same industry. A disciplined workforce review can reveal whether execution quality is improving beneath the top-line numbers.
Compass Therapeutics Manpower Efficiency
Return on Compass Therapeutics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.7M | |
| Net Loss Per Executive | 4.4M | |
| Working Capital Per Employee | 3.2M | |
| Working Capital Per Executive | 8.3M |
Popular Tools for Compass Stock analysis
| Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |